Related references
Note: Only part of the references are listed.A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520
Soham D. Puvvada et al.
LEUKEMIA & LYMPHOMA (2016)
Langerhans cell histiocytosis shows distinct cytoplasmic expression of major histocompatibility class II antigens
Lucas Redd et al.
JOURNAL OF HEMATOPATHOLOGY (2016)
Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphoma
Sarah T. Wilkinson et al.
BLOOD (2012)
Lack and/or aberrant localization of major histocompatibility class II (MHCII) protein in plasmablastic lymphoma
Monika Schmelz et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
Nathalie A. Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Immunohistochemical Methods for Predicting Cell of Origin and Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab
Paul N. Meyer et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte
Bertrand Coiffier et al.
BLOOD (2010)
Mechanisms of Disease: Aggressive Lymphomas.
Georg Lenz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
Mojgan Ahmadzadeh et al.
BLOOD (2009)
CIITA or RFX coding region loss of function mutations occur rarely in diffuse large B-cell lymphoma cases and cell lines with low levels of major histocompatibility complex class II expression
Lisa M. Rimsza et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
PD-1 Is a Regulator of NY-ESO-1-Specific CD8+ T Cell Expansion in Melanoma Patients
Julien Fourcade et al.
JOURNAL OF IMMUNOLOGY (2009)
Decreased major histocompatibility complex class II expression in diffuse large B-cell lymphoma does not correlate with CpG methylation of class II transactivator promoters III and IV
Sarah T. Wilkinson et al.
LEUKEMIA & LYMPHOMA (2009)
Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP
Lisa M. Rimsza et al.
BLOOD (2008)
Distribution patterns of dendritic cells and T cells in Diffuse large B-cell lymphomas correlate with prognoses
Kung-Chao Chang et al.
CLINICAL CANCER RESEARCH (2007)
HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma
Arjan Diepstra et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival
Robin A. Roberts et al.
BLOOD (2006)
Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions
LM Rimsza et al.
BLOOD (2006)
Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach
JS Abramson et al.
BLOOD (2005)
Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project
LM Rimsza et al.
BLOOD (2004)
Share Paper
